



(11)

EP 3 000 467 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:

01.03.2023 Bulletin 2023/09

(21) Application number: 15188350.1

(22) Date of filing: 24.03.2010

(51) International Patent Classification (IPC):
A61K 31/4709 (2006.01) A61P 35/00 (2006.01)

(52) Cooperative Patent Classification (CPC):

(C-Sets available)

A61K 31/4706; A61K 31/4709; A61K 39/39558;
A61K 45/06; A61P 15/00; A61P 19/10;
A61P 35/00; A61P 43/00

(Cont.)

(54) **TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER**

BEHANDLUNGSSCHEMA MIT NERATINIB FÜR BRUSTKREBS

RÉGIME DE TRAITEMENT À L'AIDE DE NÉRATINIB POUR LE CANCER DU SEIN

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: 06.04.2009 US 166796 P

(43) Date of publication of application:

30.03.2016 Bulletin 2016/13

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

10722215.0 / 2 416 774

(73) Proprietor: Wyeth LLC
New York, NY 10017 (US)

(72) Inventors:

- BERKENBLIT, Anna
Needham,
MA 02494 (US)
- BINLICH, Florence
F-92410 Ville D'Avray (FR)
- GOSS, Paul
Wellesley, MA Massachusetts 02482 (US)

(74) Representative: Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München (DE)

(56) References cited:
WO-A1-2007/056118

- WONG KWOK-K ET AL: "A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.", 1 April 2009 (2009-04-01), CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 APR 2009 LNKD-PUBMED:19318484, VOL. 15, NR. 7, PAGE(S) 2552 - 2558, XP002591681, ISSN: 1078-0432 * See abstract, page 2553, first column and passage bridging pages 2556 and 2557: phase II trials indicates that neratinib has antitumoral activity in patients affected by breast cancer positive to HER-2/neu (ErbB-2), previously treated with trastuzumab *
- BEDARD PHILIPPE L ET AL: "Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.", March 2009 (2009-03), CURRENT CANCER DRUG TARGETS MAR 2009 LNKD-PUBMED:19275756, VOL. 9, NR. 2, PAGE(S) 148 - 162, XP009136078, ISSN: 1873-5576 * See abstract and page 148, second column: cancer progress in patients on trastuzumab therapy; Developing strategies to circumvent resistance to trastuzumab is imperative in the treatment of HER-2 positive breast cancer ** See page 151, table 1: strategies to overcome trastuzumab resistance; see in particular the three references to HKI-272 ** See page 154 column 1: "strategies to overcome trastuzumab resistance" and see page 157, passage bridging columns 1-2: HKI-272 produces response in patients affected by refractory HER-2 positive cancer *

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- BURSTEIN H ET AL: "HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer.", December 2007 (2007-12), BREAST CANCER RESEARCH AND TREATMENT, VOL. 106, NR. SUPPL. 1, PAGE(S) S268, 30TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 13 -16, 2007, XP002591682, ISSN: 0167-6806 * See abstract: clinical phase II study involving administration of neratinib (HKI-272), to patients affected by advanced breast cancer previously administered trastuzumab *
- WIDAKOWICH C ET AL: "HER-2 positive breast cancer: What else beyond trastuzumab-based therapy?", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NL LNKD- DOI:10.2174/187152008784533062, vol. 8, no. 5, 1 June 2008 (2008-06-01), pages 488-496, XP008114462, ISSN: 1871-5206
- WISSNER ALLAN ET AL: "The development of HKI-272 and related compounds for the treatment of cancer.", August 2008 (2008-08), ARCHIV DER PHARMAZIE AUG 2008 LNKD- PUBMED:18493974, VOL. 341, NR. 8, PAGE(S) 465 - 477, XP002591683, ISSN: 0365-6233 * See abstract and see page 475, passage bridging columns 1-2: HKI-272 is an irreversible HER-2 inhibitor which maintains activity against cancers resistant to reversible inhibitors (gefitinib and erlotinib) ** See page 476, passage bridging columns 1-2: HKI-272 produces 51% response in patients affected by breast cancer after trastuzumab therapy *
- ILIADIS A ET AL: "APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics", COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/0169-2607(92)90103-E, vol. 38, no. 4, 1 August 1992 (1992-08-01) , pages 227-239, XP024237123, ISSN: 0169-2607 [retrieved on 1992-08-01]
- JELLIFFE R W ET AL: "Adaptive control of drug dosage regimens: Basic foundations, relevant issues, and clinical examples", INTERNATIONAL JOURNAL OF BIO-MEDICAL COMPUTING, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IE LNKD-DOI:10.1016/0020-7101(94)90091-4, vol. 36, no. 1-2, 1 June 1994 (1994-06-01) , pages 1-23, XP026260200, ISSN: 0020-7101 [retrieved on 1994-06-01]
- HUDIS CLIFFORD A ET AL: "Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 MAY 2007, vol. 25, no. 15, 20 May 2007 (2007-05-20), pages 2127-2132, XP002754386, ISSN: 1527-7755

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/4709, A61K 2300/00;
A61K 39/39558, A61K 2300/00

Description**BACKGROUND OF THE INVENTION**

5 **[0001]** Breast cancer is the most frequently diagnosed malignancy in women and the leading cause of cancer mortality in women worldwide. The global incidence of breast cancer is estimated to reach 5 million women in the next decade [Parkin, DM and Fernandez LM, Use of statistics to assess the global burden of breast cancer. *Breast Journal*. 2006; (12, Suppl 1):S70-80; World Health Statistics. 2008, World Health Organization.] In 2007, breast cancer accounted for approximately 540,000 deaths worldwide [World Health Organization Fact Sheet No. 297. 2008; available from WHO web site.]

10 **[0002]** The erbB (erythroblastic leukemia viral oncogene homolog) family of TKIs (Tyrosine Kinase Inhibitors) consists of 4 members: erbB-1 (EGFR [epidermal growth factor receptor]), erbB-2 (HER-2, neu), erbB-3 (HER-3) and erbB-4 (HER-4). The erbB family of receptors is involved in cell proliferation, tumorigenesis, and metastasis and is abnormally expressed in multiple tumor types. HER2-positive breast cancers, i.e., those which test positive for the protein called 15 human EGFR, are associated with Erb-2-protein overexpression or erbB-2 gene amplification in breast cancer tumors has been associated with more aggressive clinical disease and poorer prognosis [Slamon D, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987 (235):177-182].

20 **[0003]** Trastuzumab, a humanized monoclonal antibody that selectively binds to the human erbB-2 receptor, improves the prognosis of women with erbB-2-positive breast cancer. In patients with erbB-2 overexpressing metastatic breast 25 cancer, trastuzumab in combination with chemotherapy improves tumor regression, extends time to tumor progression and prolongs median survival over chemotherapy alone resulting in its approval as first-line treatment in the metastatic setting. [Ligibel JA and Winer EP, Trastuzumab/chemotherapy combinations in metastatic breast cancer. *Seminars in Oncology*. 2002; 29(3 Suppl 11): 38-43]. Herceptin (trastuzumab) [Package insert, Genentech (2008)]. Trastuzumab has also been approved for use in the adjuvant setting in combination with other drugs for treatment of erbB-2 overexpressing node positive or node negative (estrogen receptor/progesterone receptor [ER/PgR] negative) metastatic breast 30 cancer. Thus, trastuzumab has been used as part of a treatment regimen consisting of (a) doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, (b) a regimen with docetaxel and carboplatin, and (c) as a single agent following multimodality anthracycline based therapy.

35 **[0004]** The current standard of care after diagnosis with HER+ breast cancer is surgery, followed by adjuvant treatment for a year. Standard adjuvant treatment is some combination of chemotherapy, radiation, hormonal therapy for ER/PR positive disease and trastuzumab. Despite completion of adjuvant therapy, patients with early stage breast cancer remain at risk for relapse. Published reports of trastuzumab therapy show disease-free-survival rates ranging from 80.6% [Smith I, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. *Lancet*. 2007; 369:29-36] at three years to 85.9 % to 82% at four years [Perez EA, et al., Updated results 40 of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. *Journal of Clinical Oncology*. ASCO Annual Meeting Proceedings. 2007; 25(18S): 512 and Slamon D, et al., Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Presentation by Slamon D. SABCC 2006].

45 **[0005]** HKI-272 (neratinib) has been described for the treatment of neoplasms [US Patent 6,288,082]. Neratinib is a potent irreversible pan erbB inhibitor. Neratinib is an orally available small molecule that inhibits erbB-1, erbB-2 and erbB-4 at the intracellular tyrosine kinase domains, a mechanism of action that is different from trastuzumab. Neratinib reduces erbB-1 and erbB-2 autophosphorylation, downstream signaling, and the growth of erbB-1 and erbB-2 dependent cell lines. Preclinical data suggest that neratinib will have antitumor activity in erbB-1 - and/or erbB 2-expressing carcinoma cell lines, with cellular IC50 <100 nM [Rabindran SK, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. *Cancer Research*. 2004;64(11):3958-65]. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors is reported in *Clinical Cancer Research* 2009;15(7):2552-2558.

50 **[0006]** What are needed are drugs and regimens which improve patient survival rates and/or drugs and regimens which decrease recurrence of breast cancer following completion of primary and adjuvant treatment.

SUMMARY OF THE INVENTION

55 **[0007]** The invention is defined in the claims.

DETAILED DESCRIPTION OF THE INVENTION

60 **[0008]** In one embodiment, the invention provides an extended adjuvant regimen for treatment of HER-2/neu overexpressed/amplified cancer comprising delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified


cancer patients. Such extended adjuvant therapy involves beginning the neratinib therapy at the completion of adjuvant therapy with trastuzumab. This extended adjuvant therapy is used to provide improved invasive disease-free survival (IDFS) or disease-free survival (DFS) - ductal carcinoma *in situ* (DCIS) and/or improvements in overall survival, time to distant recurrence, and/ distant disease-free survival.

5 [0009] As used herein, invasive disease-free survival (IDFS) is defined as time from date of randomization to date of an IDFS event, including: invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death from any cause, invasive contralateral breast cancer, and second primary invasive cancer (nonbreast). DFS-DCIS is defined as the time from randomization to the first occurrence of any IDFS event or ductal carcinoma *in situ*. Distant Disease Free Survival (DDFS) is the time from randomization to the first distant recurrence, or death from any cause. Time to distant recurrence (TTDR) is defined as the time between randomization and the date of the first distant tumor recurrence, ignoring locoregional recurrences and second breast or nonbreast cancers and taking into account deaths before recurrence of distant breast cancer as censoring events.

10 [0010] Thus, the extended adjuvant therapy of the invention using neratinib increases the disease-free survival by reducing the risk of recurrence or death. In one embodiment, the extended neratinib adjuvant therapy reduces the risk, 15 i.e., hazard rate, of cancer recurrence or death by 30% or 20% compared to conventional observation after trastuzumab therapy.


20 [0011] In another embodiment, using the extended neratinib regimen described herein, less than 15%, less than 10% and/or less than 5% of patients who have received primary and adjuvant therapy have cancer at three years post-inception of therapy. In still another embodiment, using the extended neratinib regimen described herein, less than 20%, less than 15% and/or less than 5% of patients who have received primary and adjuvant therapy have cancer at five years post inception of therapy.

[0012] As used herein, neratinib refers to HKI-272, which has the following core structure:



in its free base form. Optionally, a pharmaceutically acceptable salt or hydrate thereof may be used. The core structure represented above is a particular HKI-272 compound, called HKI-272 or neratinib, which has the chemical name [(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide].

40 [0013] Although currently less preferred, another HKI-272 compound may be used in the place of neratinib. "A HKI-272 compound" refers, in one embodiment, to a compound derived from the core structure of neratinib shown above. Suitable derivatives may include, e.g., an ester, ether, or carbamate. Such an HKI-272 compound may have the structure:



wherein:

R¹ is halogen;

R² is pyridinyl, thiophenyl, pyrimidinyl, thiazolyl, or phenyl, wherein R² is optionally substituted with up to three substituents;

R³ is O or S;

5 R⁴ is CH₃ or CH₂CH₂OCH₃;

R⁵ is CH₃ or CH₂CH₃; and

n is 0 or 1.

[0014] The term "halogen" as used herein refers to Cl, Br, I, and F.

[0015] Also encompassed are pharmaceutically acceptable salts, hydrates, and prodrugs of neratinib and/or the other HKI compounds described herein. "Pharmaceutically acceptable salts and esters" refers to salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include, e.g., salts that can be formed where acidic protons present in the compounds are capable of reacting with inorganic or organic bases. Suitable inorganic salts include, e.g., those formed with the alkali metals or alkaline earth metals, e.g. sodium, potassium, magnesium, calcium, aluminum. Suitable organic salts also include, e.g., those formed with organic bases such as the amine bases, e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like, and those which can form N-tetraalkylammonium salts such as N-tetrabutylammonium salts. Pharmaceutically acceptable salts can also include acid addition salts formed from the reaction of basic moieties, such as amines, in the parent compound with inorganic acids (e.g., hydrochloric and hydrobromic acids) and organic acids (e.g., acetic acid, citric acid, maleic acid, propionic, lactic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benzenesulfonic acid naphthalenesulfonic, toluenesulfonic, camphorsulfonic). Other suitable examples of pharmaceutically acceptable salts include, but are not limited, to sulfate; citrate, acetate; oxalate; chloride; bromide; iodide; nitrate; bisulfate; phosphate; acid phosphate; isonicotinate; lactate; salicylate; acid citrate; tartrate; oleate; tannate; pantothenate; 25 bitartrate; ascorbate; succinate; maleate; gentisinate; fumarate; gluconate; glucuronate; saccharate; formate; benzoate; glutamate; methanesulfonate; ethanesulfonate; benzenesulfonate; p-toluenesulfonate; pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)); and salts of fatty acids such as caproate, laurate, myristate, palmitate, stearate, oleate, linoleate, and linolenate salts.

[0016] Pharmaceutically acceptable esters include esters formed from carboxy, sulfonyloxy, and phosphonoxy groups present in the compounds of the invention, e.g., straight chain alkyl esters having from 1 to 6 carbon atoms or branched chain alkyl groups containing 1 to 6 carbon atoms, including methyl, ethyl, propyl, butyl, 2-methylpropyl and 1,1-dimethyl-ethyl esters, cycloalkyl esters, alkylaryl esters, benzyl esters, and the like. When there are two acidic groups present, a pharmaceutically acceptable salt or ester can be a mono-acid-mono-salt or ester or a di-salt or ester; and similarly where there are more than two acidic groups present, some or all of such groups can be salified or esterified. Compounds utilized herein may be present in unsalified or unesterified form, or in salified and/or esterified form, and the naming of such compounds is intended to include both the original (unsalified and unesterified) compound and its pharmaceutically acceptable salts and esters. Also, one or more compounds utilized herein may be present in more than one stereoisomeric form, and the naming of such compounds is intended to include all single stereoisomers and all mixtures (whether racemic or otherwise) of such stereoisomers.

[0017] The preparation of HKI-272 compounds, of which neratinib is a species, are described in detail in US Patent Application Publication No. 2005/0059678, which is hereby incorporated by reference. See, also, US Patent Nos. 6,288,082, US Patent No. 6,002,008, US Patent No. 6,297,258 and US Patent Application Publication No. 2007/0104721, which are hereby incorporated by reference. The methods described in these documents can also be used to prepare neratinib and/or the other HKI-272 and substituted 3-quinoline compounds used herein and are hereby incorporated by reference. In addition to the methods described in these documents, International Patent Publication Nos. WO-96/33978 and WO-96/33980, which are hereby incorporated by reference, describe methods that are useful for the preparation of these HKI-272 compounds. Although these methods describe the preparation of certain quinazolines, they are also applicable to the preparation of correspondingly substituted 3-cyanoquinolines and are hereby incorporated by reference.

[0018] The term "treating" or "treatment" refers to the administration of the neratinib to a subject to prevent or delay, to alleviate, or to arrest or inhibit development of the symptoms or conditions associated with neoplasms.

[0019] Trastuzumab, and methods of making and formulating same have been described. See, e.g., US Patent 6,821,515; US Patent No. 6,399,063 and US Patent No. 6,387,371. Trastuzumab is available commercially from Genentech under the name "Herceptin". As used herein, the term "a trastuzumab" includes includes trastuzumab and altered forms of, and derivatives of, trastuzumab. The term "a trastuzumab" includes agents that target the same epitope on the Her-2 receptor as targeted by trastuzumab. The epitope is known from H.S. Cho et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, *Nature* 421 (2003), pp. 756-760.

[0020] As used herein, neoplasms which amplify/overexpress erB-2 (used interchangeably with Her-2 and neu) include certain breast cancers and other neoplasms, which may include, ovarian, bladder, gastric, pancreatic, colorectal, prostate,

and lung cancers, including non-small cell lung cancers. Other neoplasms in which ErbB1 is expressed or overexpressed include a variety of solid human tumors, including non-small cell lung (NSCL), prostate, breast, colorectal, and ovarian cancers. Methods for screening samples to determine if the neoplasm overexpresses erb-1 and/or erb-2/Her-2 are known to those of skill in the art.

5

Primary and Adjuvant Anti-Neoplastic Therapy

[0021] As defined herein, primary therapy is the initial therapy provided to a patient following diagnosis with a neoplasm, such as a HER-2/neu overexpressed/amplified neoplasm. Primary therapy is also called definitive local therapy. Primary therapy for a HER-2/neu overexpressed/amplified neoplasm includes surgery (in the case of breast cancer this may include lumpectomy, modified radical mastectomy, mastectomy) and/or radiation, alone or in combination. Adjuvant therapy refers to therapy conventionally provided following initial or primary therapy to increase the likelihood of a cure. Currently, standard adjuvant therapy for a HER-2/neu overexpressed/amplified neoplasm includes, e.g., chemotherapy and/or antibody therapy. Typically, if one or more of these adjuvant therapies is delivered prior to primary therapy (e.g., surgery), it is termed neoadjuvant therapy. Throughout the following portions of the specification, the term "neo/adjuvant" is used as shorthand to refer to both neoadjuvant and standard adjuvant therapy. One or more types of adjuvant therapy may be delivered concomitantly.

[0022] In one embodiment, the patient may have been subject to chemotherapy involving delivery of either an anthracycline or a taxane or any cyclophosphamide, methotrexate and 5-fluorouracil regimen. Such chemotherapies may include one or more of an anthracycline, such as doxorubicin, cyclophosphamide, paclitaxel, docetaxel, and carboplatin. Another suitably neo/adjuvant therapy is a multi-modality anthracycline based therapy. Still other neo/adjuvant therapies include lapatinib [Lapatinib ditoxylate, TYKERB®], pertuzumab [Roche, Genentech], bevacizumab [Avastin®, Genentech], trastuzumab-DM-1 [Genentech], amongst others. The selection of the neoadjuvant or adjuvant therapy is not a limitation of the present invention. The extended adjuvant therapy of the invention begins following completion of therapy with trastuzumab. Trastuzumab is typically delivered after completion of or concurrent with chemotherapy as maintenance therapy. For trastuzumab, single doses and multiple doses are contemplated. In one embodiment, a single loading dose of trastuzumab is administered as a 90-minute intravenous infusion in a range of about 4- 5 mg/kg on day 1, followed by about 2 mg/kg per week starting on day 8. Typically, 3 weeks is 1 cycle. From 1, to 2 to 3, weeks may be provided between cycles. In another embodiment, trastuzumab is delivered with an every-3-weeks dosing schedule, using 8 mg/kg as a loading dose and 6 mg/kg as the maintenance dose. Trastuzumab may also be given at a dose of 6 mg/kg once every 3 - 4 weeks. Still other trastuzumab dosing regimens may be designed and utilized.

[0023] In one embodiment, the patient may have received primary as well as, in addition to trastuzumab neo/adjuvant therapy, other neo/adjuvant therapy. In one embodiment, one or more of the adjuvant therapies may continue following completion of the trastuzumab therapy during the extended adjuvant therapy. Suitably, neither the primary therapy nor the neo/adjuvant therapy involves neratinib therapy prior to the onset of the extended neratinib regimen of the invention.

Extended Neratinib Regimen of Invention

[0024] In one embodiment, the extended neratinib regimen described herein is initiated at about one year, about two years or about three years following the start of primary therapy. The extended neratinib adjuvant regimen is started following the completion of neo/adjuvant therapy with trastuzumab.

[0025] The extended regimen described herein may start following completion of at least one dose, at least 3 week cycle, at least three 3 week cycles, at least four months, at least six months, at least eight months, or at least one year of trastuzumab neo/adjuvant therapy, and is initiated at least two weeks, at least about one month, at least about six months, at least about nine months, or at about one year to four years following completion of the trastuzumab therapy.

[0026] As described herein, the extended neratinib regimen is used to decrease the rate of recurrence of HER-2/neu overexpressed/amplified breast cancer in patients. These rates may be measured at a time point six months, one year, three years, or five years following inception of treatment. The regimen involves providing neratinib to these patients following primary and neo/adjuvant therapy. In another embodiment, the extended neratinib is used to improve invasive disease free survival, DFS-DCIS, distant disease free survival, and/or time to distant recurrence in cancer patients.

[0027] This extended adjuvant therapy of the invention may involve only a single dose of neratinib post-completion of trastuzumab therapy. However, in another embodiment, the extended neratinib regimen is administered over a period of at least six months, at least one year, at least 18 months, or for about 8 months to about 5 years, about 12 months (one year) to about three years.

[0028] As used herein, the term "providing" with respect to providing a neratinib, means either directly administering the compound or composition, or administering a prodrug, derivative, or analog which will form an effective amount of the neratinib compound within the body.

[0029] As used herein and except where noted, the terms "individual", "subject" and "patient" are used interchangeably,

and refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, non-human primates, and humans. Desirably, the term "individual", "subject" or "patient" refers to a human. In most embodiments, the subjects or patients are in need of the therapeutic treatment. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the claimed regimen can be administered.

[0030] As used herein, the term "effective amount" or "pharmaceutically effective amount" when administered to a subject to treat a neoplasm, is sufficient to inhibit, slow, reduce, or eliminate lesions or tumor growth in a subject, or to inhibit, slow, or reduce progression of disease and/or to increase progression-free survival rate of the subject.

[0031] Neratinib (or the selected HKI-272 compound) can be administered, e.g., orally, at a dose range of about 0.01 to 100 mg/kg. In one embodiment, neratinib is administered at a dose range of about 0.1 to about 90 mg/kg. In another embodiment, neratinib is administered at a dose range of about 1 to about 80 mg/kg. In a further embodiment, neratinib is administered at a dose range of about 10 to about 70 mg/kg. In yet another embodiment, neratinib is administered at a dose range of about 15 to about 60 mg/kg. In still a further embodiment, neratinib is administered at a dose range of about 20 to about 240 mg per day, at least about 40 mg, at least about 120 mg, or at least about 160 mg, on the days in the cycle on which it is administered. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer when the compound is delivered by another route.

[0032] In one embodiment, the oral dosage of neratinib is at least about 700 mg/week. In another embodiment, the oral dosage of neratinib is about 800 mg/week to at least to about 1700 mg/week. In another embodiment, the oral dosage of neratinib is about 840 mg/week to about 1680 mg/week. In another embodiment, the oral dosage of neratinib is about 900 mg/week to about 1600 mg/week. In a further embodiment, the oral dosage of neratinib is about 1000 mg/week to about 1500 mg/week. In yet another embodiment, the oral dosage of neratinib is about 1100 mg/week to about 1400 mg/week. In still a further embodiment, the oral dosage of neratinib is about 1200 mg/week to about 1300 mg/week. Precise dosages are determined by the administering physician based on experience with the individual subject to be treated.

[0033] For neratinib, it is desired that the compound be in the form of a unit dose. Neratinib can be administered at a dose range of about 0.01 to 100 mg/kg or at a dose range of 0.1 to 10 mg/kg. In one embodiment, neratinib is administered orally from 1 to 6 times a day, more usually from 1 to 4 times a day. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit dose forms may contain from 0.1 to 300 mg of neratinib, from 2 to 100 mg, at a dose of 120 mg to 300 mg daily, or 240 mg daily. Alternatively, neratinib may be administered through another suitable route, e.g., intravenous. In still another embodiment, neratinib is administered once a week. In certain situations, dosing with neratinib may be delayed or discontinued for a brief period (e.g., 1, 2 or three weeks) during the course of treatment. Such a delay or discontinuation may occur once, or more, during the course of treatment. The effective amount will be known to one of skill in the art; it will also be dependent upon the form of the compound. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer.

[0034] In one embodiment, suitable examples of pharmaceutical carriers used herein include, but are not limited to, excipients, diluents, fillers, disintegrants, lubricants and other agents that can function as a carrier. The term "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous. Pharmaceutical compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985). Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable. Suitable pharmaceutically-acceptable excipients or carriers for a tablet or caplet formulation include, e.g., inert excipients such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or alginic acid; binding agents such as gelatin or starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl 4-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet or caplet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance using conventional coating agents and procedures well known in the art.

[0035] In one embodiment, the invention provides an extended regimen for treatment of HER-2/neu overexpressed/amplified cancer comprising delivering a course of extended neratinib therapy to HER-2/neu overexpressed/amplified cancer patients. Such extended therapy involves beginning the neratinib therapy at the completion of surgical/or and adjuvant therapy. This extended therapy is used to provide improved invasive disease-free survival and/or improvements in overall survival, time to distant recurrence, and distant disease-free survival.

[0036] As described herein, the extended neratinib regimen is initiated at least one, at least two, or at least three years

following inception of initial therapy. In one embodiment, neratinib therapy is initiated at least 2 weeks after and up to about four years following the completion of primary and standard neo/adjuvant therapy.

[0037] In one embodiment, selected concomitant therapies may be used in conjunction with the extended neratinib regimen. For example, patients may be further undergoing concomitant therapy with bisphosphonates for osteopenia or osteoporosis. In another example, patients may be further undergoing concomitant endocrine therapy. Optionally, such concomitant therapies may be non-adjuvant therapies, but rather are for treatment of other conditions or symptoms which the patient may have.

Pharmaceutical Packs/Kits

[0038] The invention includes a product or pharmaceutical pack containing a course of an anti-neoplastic treatment for one individual mammal comprising one or more container(s) having one, one to four, or more unit(s) of neratinib and, optionally, one, one to four, or more unit(s) of another active agent.

[0039] In another embodiment, pharmaceutical packs contain a course of anti-neoplastic treatment for one individual mammal comprising a container having a unit of a rapamycin in unit dosage form, a containing having a unit of neratinib and optionally, a container with another active agent.

[0040] In some embodiments, the compositions of the invention are in packs in a form ready for administration. In other embodiments, the compositions of the invention are in concentrated form in packs, optionally with the diluent required to make a final solution for administration. In still other embodiments, the product contains a compound useful in the invention in solid form and, optionally, a separate container with a suitable solvent or carrier for the compound useful in the invention.

[0041] In still other embodiments, the above packs/kits include other components, e.g., instructions for dilution, mixing and/or administration of the product, other containers, syringes, needles, etc. Other such pack/kit components will be readily apparent to one of skill in the art.

[0042] The following examples illustrate of the uses of the combinations of the invention. It will be readily understood that alterations or modifications, e.g., in the formulation of the components, the routes of delivery, and the dosing, can be made for reasons known to those of skill in the art.

EXAMPLES

[0043] Neratinib as a single agent has been studied in a phase 2 trial in subjects with metastatic erbB-2 positive breast cancer. Sixty-six subjects with prior trastuzumab based therapy were enrolled into Arm A; 70 subjects without any prior trastuzumab exposure were enrolled into Arm B. Objective response rate and median progression free survival were used as estimates of antitumor activity.

[0044] According to preliminary data based on independent radiology assessment, among subjects with prior trastuzumab treatment, the overall response rate (ORR) was 26% (95% confidence index (CI)) and median progression-free survival (PFS) was 23 weeks (95% CI). For subjects without prior exposure to trastuzumab, the ORR was 57% (95% CI) and median PFS was 40 weeks (95% CI). The antitumor activity in arm A provides the basis for the testing neratinib as a single agent in trastuzumab refractory subjects.

[0045] In Arm A, the median duration of trastuzumab exposure was 60 weeks. Twenty-eight (28%) of subjects received trastuzumab as adjuvant or neoadjuvant therapy. The majority (48%) of subjects received one trastuzumab based regimen in the metastatic setting and approximately 43% received a second or third trastuzumab based regimen for metastatic disease. Arm A subjects also had extensive prior cytotoxic treatment with 53% of subjects receiving 2-3 prior regimens and another 27% receiving > 3 prior cytotoxic regimens. Taken together, these treatment characteristics described a heavily pretreated, and likely refractory, study population in Arm A. As such, an ORR of 26% in a refractory population suggests that neratinib is likely to be a highly active agent for erbB-2 positive breast cancer.

[0046] Main adverse event associated with neratinib is diarrhea, which has been generally well manageable with medication, treatment interruption, or dose modification. Other common adverse events are nausea, vomiting, fatigue, and anorexia.

[0047] In a randomized, double-blind, placebo-controlled phase 3 trial, neratinib is compared against placebo following trastuzumab in women with early-stage HER-2/neu overexpressed/amplified breast cancer. Subjects must have completed a course of prior adjuvant trastuzumab. If less than 12 months of trastuzumab have been given, at least 8 prior doses must have been given and it must be specified that the subject is either not eligible or unable to receive further adjuvant therapy with trastuzumab. Following completion of a course of prior adjuvant therapy involving at least 8, and preferably 12 months of trastuzumab, subjects are eligible for treatment with the regimen described herein. The last

dose of trastuzumab must have been given > 2 weeks and < 4 years from inception of randomization. Randomization will be stratified by the following factors: ER and/or PgR positive vs. ER and PgR negative; nodal status (0, 1-3, 4 or more); < or > 3 years from diagnosis; trastuzumab given sequentially vs. concurrently with chemotherapy.

[0048] Eligible subjects are randomly assigned in a 1:1 ratio to one of the following two arms: Neratinib 240 mg daily for 1 year or Placebo daily for 1 year. After discontinuing study treatment, subjects will continue to be followed for disease recurrence and survival until the planned number of invasive disease free survival (IDFS) events has been reached, and for survival thereafter until the end of the study. The primary efficacy endpoint of IDFS and time-to-event secondary endpoints will be analyzed using a stratified log-rank test. The hazard ratio and the corresponding 95% confidence interval will be derived from a stratified Cox proportional hazards regression model [DR Cox, 1972, "Regression Models and Life Tables (with Discussion)", Journal of the Royal Statistical Society, Series B 34:187-220]. The median times to event and the associated 95% confidence intervals will be estimated using the Kaplan-Meier method [Kaplan, E.L. and Meier, Paul. "Nonparametric estimation from incomplete observations." J. Am. Stat. Assoc. 53, 457-481 (1958)]. The primary efficacy analysis will be conducted on the intent to treat population, defined as all subjects randomized. Adverse events and serious adverse events will be summarized by treatment arm for the safety population, defined as all subjects dosed with neratinib or placebo. The incidence of grade 3 or higher diarrhea will also be summarized and differences across treatment arms will be tested using the Mantel-Haenszel test. [Mantel N & Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Nat. Cancer Inst. 22:719-48, 1959].

20 Claims

1. Neratinib or a pharmaceutically acceptable salt or hydrate thereof for use in a method for treating HER-2/neu overexpressed/amplified breast cancer in an extended neratinib adjuvant regimen, wherein the method comprises delivering the extended neratinib adjuvant regimen to a HER-2/neu overexpressed/amplified breast cancer patient,

25 wherein the extended neratinib adjuvant regimen is started at least 2 weeks, at least one month, at least six months or at least nine months following the completion of a trastuzumab adjuvant therapy, and wherein the extended neratinib adjuvant regimen is administered over a period of at least six months, at least 12 months, at least 18 months, 8 months to 5 years or 12 months to three years.

30 2. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to claim 1, wherein the extended neratinib adjuvant regimen decreases the rate of recurrence of HER-2/neu overexpressed/amplified breast cancer in the patient.

35 3. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to claim 1 or 2, wherein the extended neratinib adjuvant regimen improves invasive disease-free survival (IDFS), disease-free survival - ductal carcinoma in situ (DFS-DCIS), distant disease-free survival (DDFS), and/or time to distant recurrence (TTDR) in the patient.

40 4. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to any one of claims 1 to 3, wherein neratinib or the pharmaceutically acceptable salt or hydrate thereof is in the form of a unit dose.

45 5. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to claim 4, wherein the unit dose form contains from 0.1 to 300 mg or from 2 to 100 mg of neratinib or the pharmaceutically acceptable salt or hydrate thereof.

6. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to claim 4 or 5, wherein the unit dose form is a tablet, a capsule or a powder in sachets or vials.

50 7. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to any one of claims 4 to 6, wherein neratinib or the pharmaceutically acceptable salt or hydrate thereof is orally administered from 1 to 6 times a day.

8. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to claim 7, wherein neratinib or the pharmaceutically acceptable salt or hydrate thereof is orally administered from 1 to 4 times a day.

55 9. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to any one of claims 4 to 8, wherein neratinib or the pharmaceutically acceptable salt or hydrate thereof is administered at a dose of 120 mg to

300 mg daily, or 240 mg daily.

10. Neratinib or the pharmaceutically acceptable salt or hydrate thereof for use according to any one of claims 1 to 9, wherein the pharmaceutically acceptable salt is a sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methane sulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, 1,1'-methyleno-bis-(2-hydroxy-3-naphthoate), caproate, laurate, myristate, palmitate, stearate, oleate, linoleate, or linolenate salt.

10

Patentansprüche

1. Neratinib oder ein pharmazeutisch akzeptables Salz oder Hydrat davon zur Verwendung in einem Verfahren zur Behandlung von Brustkrebs **gekennzeichnet durch** die Überexpression/Amplifikation von HER-2/neu in einem erweiterten adjuvanten Neratinib-Dosierungsschema, wobei das Verfahren die Anwendung des erweiterten adjuvanten Neratinib-Dosierungsschemas bei einer Patientin mit einem durch die Überexpression/Amplifikation von HER-2/neu gekennzeichneten Brustkrebs umfasst,

20 wobei das erweiterte adjuvante Neratinib-Dosierungsschema mindestens 2 Wochen, mindestens ein Monat, mindestens sechs Monate oder mindestens neun Monate im Anschluss an die Beendigung einer adjuvanten Trastuzumabtherapie eingeleitet wird, und
wobei das erweiterte adjuvante Neratinib-Dosierungsschema über einen Zeitraum von mindestens sechs Monaten, mindestens 12 Monaten, mindestens 18 Monaten, 8 Monaten bis 5 Jahren oder 12 Monaten bis drei Jahren verabreicht wird.

2. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach Anspruch 1, wobei das erweiterte adjuvante Neratinib-Dosierungsschema die Wiederauftretensrate von einem durch die Überexpression/Amplifikation von HER-2/neu gekennzeichneten Brustkrebs bei der Patientin verringert.

30 3. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach Anspruch 1 oder 2, wobei das erweiterte adjuvante Neratinib-Dosierungsschema das invasivkrankheitsfreie Überleben (IDFS), das krankheitsfreie Überleben - duktales Karzinom *in situ* (DFS- DCIS), das fernkrankheitsfreie Überleben (DDFS) und/oder die Zeit bis distantem Wiederauftreten (TTDR) bei der Patientin verbessert.

35 4. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach einem der Ansprüche 1 bis 3, wobei Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon in der Form einer Einheitsdosis ist.

40 5. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach Anspruch 4, wobei die Einheitsdosis von 0,1 bis 300 mg oder von 2 bis 100 mg Neratinib oder des pharmazeutisch akzeptablen Salzes oder Hydrats davon enthält.

45 6. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach Anspruch 4 oder 5, wobei die Einheitsdosis eine Tablette, eine Kapsel oder ein Pulver in Päckchen oder Ampullen ist.

7. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach einem der Ansprüche 4 bis 6, wobei Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon von 1 bis 6 Mal pro Tag oral verabreicht wird.

50 8. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach Anspruch 7, wobei Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon von 1 bis 4 Mal pro Tag oral verabreicht wird.

9. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach einem der Ansprüche 4 bis 8, wobei Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon in einer Dosis von 120 mg bis 300 mg täglich oder 240 mg täglich verabreicht wird.

55 10. Neratinib oder das pharmazeutisch akzeptable Salz oder Hydrat davon zur Verwendung nach einem der Ansprüche

1 bis 9, wobei das pharmazeutisch akzeptable Salz ein Sulfat, Citrat, Acetat, Oxalat, Chlorid, Bromid, Iodid, Nitrat, Bisulfat, Phosphat, saures Phosphat, Isonicotinat, Lactat, Salicylat, saures Citrat, Tartrat, Oleat, Tannat, Pantothenat, Bitartrat, Ascorbat, Succinat, Maleat, Gentisamat, Fumarat, Gluconat, Glucaronat, Saccharat, Format, Benzoat, Glutamat, Methansulfonat, Ethansulfonat, Benzensulfonat, p-Toluolsulfonat, 1,1'-Methylen-bis-(2-hydroxy-3-naphthoat), Caproat, Laurat, Myristat, Palmitat, Stearat, Oleat, Linoleat oder Linolenatsalz ist.

Revendications

1. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser dans un procédé de traitement du cancer du sein surexprimé/amplifié par HER-2/neu dans un régime adjuvant étendu au nérasinib, dans lequel le procédé comprend l'administration du régime adjuvant étendu au nérasinib à un patient présentant un cancer du sein surexprimé/amplifié par HER-2/neu,
 - 15 dans lequel le régime adjuvant étendu au nérasinib est commencé au moins 2 semaines, au moins un mois, au moins six mois ou au moins neuf mois à la suite de l'accomplissement d'une thérapie adjuvante au trastuzumab, et
 - 20 dans lequel le régime adjuvant étendu au nérasinib est administré sur une période d'au moins six mois, au moins 12 mois, au moins 18 mois, de 8 mois à 5 ans ou de 12 mois à trois ans.
2. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon la revendication 1, dans lequel le régime adjuvant étendu au nérasinib diminue le taux de récidive de cancer du sein surexprimé/amplifié par HER-2/neu chez le patient.
3. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon la revendication 1 ou 2, dans lequel le régime adjuvant étendu au nérasinib améliore la survie sans maladie invasive (IDFS), la survie sans maladie - carcinome canalair in situ (DFS-DCIS), la survie sans maladie à distance (DDFS), et/ou le temps jusqu'à la récidive à distance (TTDR) chez le patient.
4. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon l'une quelconque des revendications 1 à 3, dans lequel le nérasinib ou le sel ou hydrate pharmaceutiquement acceptable de celui-ci est sous la forme d'une dose unitaire.
5. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon la revendication 4, dans lequel la forme de dose unitaire contient de 0,1 à 300 mg ou de 2 à 100 mg de nérasinib ou du sel ou hydrate pharmaceutiquement acceptable de celui-ci.
6. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon la revendication 4 ou 5, dans lequel la forme de dose unitaire est un comprimé, une capsule ou une poudre en sachets ou ampoules.
7. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon l'une quelconque des revendications 4 à 6, dans lequel le nérasinib ou le sel ou hydrate pharmaceutiquement acceptable de celui-ci est administré par voie orale de 1 à 6 fois par jour.
8. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon la revendication 7, dans lequel le nérasinib ou le sel ou hydrate pharmaceutiquement acceptable de celui-ci est administré par voie orale de 1 à 4 fois par jour.
9. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon l'une quelconque des revendications 4 à 8, dans lequel le nérasinib ou le sel ou hydrate pharmaceutiquement acceptable de celui-ci est administré à une dose de 120 mg à 300 mg par jour, ou de 240 mg par jour.
10. Nérasinib ou sel ou hydrate pharmaceutiquement acceptable de celui-ci à utiliser selon l'une quelconque des revendications 1 à 9, dans lequel le sel pharmaceutiquement acceptable est un sel de sulfate, citrate, acétate, oxalate, chlorure, bromure, iodure, nitrate, bisulfate, phosphate, phosphate acide, isonicotinate, lactate, salicylate, citrate acide, tartrate, oléate, tannate, pantothenate, bitartrate, ascorbate, succinate, maléate, gentisinate, fumarate, glucuronate, glucaronate, saccharate, formate, benzoate, glutamate, méthanesulfonate, éthanesulfonate, benzénésulfonate, p-toluenesulfonate, 1,1'-méthylène-bis-(2-hydroxy-3-naphtoate), caproate, laurate, myristate, palmitate,

stéarate, oléate, linoléate ou linolénate.

5

10

15

20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6288082 B [0005] [0017]
- US 20050059678 [0017]
- US 6002008 A [0017]
- US 6297258 B [0017]
- US 20070104721 [0017]
- WO 9633978 A [0017]
- WO 9633980 A [0017]
- US 6821515 B [0019]
- US 6399063 B [0019]
- US 6387371 B [0019]

Non-patent literature cited in the description

- **PARKIN, DM ; FERNANDEZ LM.** Use of statistics to assess the global burden of breast cancer. *Breast Journal*, 2006, vol. 12 (1), S70-80 [0001]
- World Health Statistics. World Health Organization, 2008 [0001]
- *World Health Organization Fact Sheet No. 297*, 2008 [0001]
- **SLAMON D.** Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*, 1987, vol. 235, 177-182 [0002]
- **LIGIBEL JA ; WINER EP.** Trastuzumab/chemotherapy combinations in metastatic breast cancer. *Seminars in Oncology*, 2002, vol. 29 (3), 38-43 [0003]
- **SMITH I et al.** 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. *Lancet*, 2007, vol. 369, 29-36 [0004]
- **PEREZ EA et al.** Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. *Journal of Clinical Oncology. ASCO Annual Meeting Proceedings*, 2007, vol. 25 (18S), 512 [0004]
- **SLAMON D et al.** Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Presentation by Slamon D. SABCC, 2006 [0004]
- **RABINDRAN SK et al.** Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. *Cancer Research*, 2004, vol. 64 (11), 3958-65 [0005]
- *Clinical Cancer Research*, 2009, vol. 15 (7), 2552-2558 [0005]
- **H.S. CHO et al.** Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature*, 2003, vol. 421, 756-760 [0019]
- Remingtons Pharmaceutical Sciences. Mack Publishing Company, 1985 [0034]
- **DR COX.** Regression Models and Life Tables (with Discussion). *Journal of the Royal Statistical Society, Series B*, 1972, vol. 34, 187-220 [0048]
- **KAPLAN, E.L. ; MEIER, PAUL.** Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.*, 1958, vol. 53, 457-481 [0048]
- **MANTEL N ; HAENSZEL W.** Statistical aspects of the analysis of data from retrospective studies of disease. *J. Nat. Cancer Inst.*, 1959, vol. 22, 719-48 [0048]